Knoll Capital Management, LLC Aldeyra Therapeutics, Inc. Transaction History
Knoll Capital Management, LLC
- $203 Million
- Q3 2024
A detailed history of Knoll Capital Management, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Knoll Capital Management, LLC holds 5,475,516 shares of ALDX stock, worth $26.1 Million. This represents 14.56% of its overall portfolio holdings.
Number of Shares
5,475,516
Previous 5,475,516
-0.0%
Holding current value
$26.1 Million
Previous $18.1 Million
62.85%
% of portfolio
14.56%
Previous 12.24%
Shares
13 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$44.2 Million1.31% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$17.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$17.2 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$8.95 Million0.24% of portfolio
-
Geode Capital Management, LLC Boston, MA1.11MShares$5.31 Million0.0% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $278M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...